ONCR 788
Alternative Names: ONCR-788Latest Information Update: 28 Jun 2025
At a glance
- Originator Oncorus
- Class Antineoplastics; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Immunologic cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Neuroendocrine tumours; Prostate cancer; Small cell lung cancer
Most Recent Events
- 28 Jun 2025 No recent reports of development identified for preclinical development in Neuroendocrine-tumours in United Kingdom (IV)
- 28 Jun 2025 No recent reports of development identified for preclinical development in Prostate-cancer in United Kingdom (IV)
- 28 Jun 2025 No recent reports of development identified for preclinical development in Small-cell-lung-cancer in United Kingdom (IV)